You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it.
NO
YES

HIGHLIGHTS

EVENTS

EIGHT, the global educational initiative on Hemophilia A and its treatment

Experts from all over the world attended the EIGHT 2018 Conference in Budapest, Hungary on 12-13 October

read more 

EVENTS

Kedrion Biopharma participates in the Mother and Child Conference in Moscow

A 50 years of Anti-D dedicated programme presented at the main Russian congress of Gynecology and Obstetrics

read more 

EVENTS

Kedrion Joins Annual PNS Conference on Neurology

The company took part in the event with a booth and a delegation of 40 int’l guests

read more 
  1. CORPORATE - 19-01-2016

    Kedrion Biopharma strengthens its position on the US market

    Granted exclusive rights to commercialize a lifesaving drug in the US

    read more 
  2. CORPORATE - 18-01-2016

    A brand new location for KEDPlasma donors in the very center of Fürth

    Plasma collected is turned into life-saving therapies to serve patients in Germany and worldwide

    read more 
  3. CORPORATE - 08-01-2016

    KEDPlasma acquires two plasma centers from ImmunoTek LLC in the US

    The acquisition is part of a five-year growth plan of supplying highest-quality plasma to Kedrion Biopharma

    read more 
  4. CORPORATE - 07-01-2016

    Human rabies Ig meets primary endpoint in U.S. pivotal phase 2/3 clinical trial

    Strategic agreement between Kedrion and Kamada for its clinical development and marketing

    read more 

Pages

For more information please contact: pressoffice@kedrion.com